Yael P. Mossé
Discovered ALK mutations in neuroblastoma and led the trials bringing crizotinib and lorlatinib to children.
Overview
Yael Mossé was first author of the 2008 discovery of ALK mutations in neuroblastoma and has led the clinical translation of ALK inhibition in children through the Children's Oncology Group and NANT consortium, including the phase 1 trials of crizotinib and lorlatinib and the addition of lorlatinib to front-line high-risk neuroblastoma therapy in COG ANBL1531. She leads the developmental therapeutics programme at CHOP.
| Title | Journal | Year |
|---|---|---|
| Identification of ALK as a major familial neuroblastoma predisposition gene | Nature | 2008 |
| Lorlatinib for ALK-driven relapsed or refractory neuroblastoma (NANT 2015-02) | Nature Medicine | 2023 |
Pages like this
not linked directly; found by shared links- PersonJohn M. Maris
Shares Children's Hospital of Philadelphia, ALK, Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
- PersonRuth Ladenstein
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
- PersonD. Ross Camidge
Shares Lorlatinib, ALK, Small-molecule kinase inhibitors and the tag alk.
- PersonNai-Kong V. Cheung
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
- Product131I-MIBG (iobenguane I-131) therapy
Shares COG ANBL1531, Neuroblastoma (paediatric).
- ProductNeladalkib
Shares Lorlatinib, ALK, Small-molecule kinase inhibitors.
- PersonStephen P. Hunger
Shares Children's Hospital of Philadelphia and the tag paediatric.
- ProductBrigatinib
Shares ALK, Small-molecule kinase inhibitors.